Circular Genomics

Our CEO, Paul Sargeant, joins the Healthcare Happenings podcast in the episode “Circular Genomics: Cracking the Brain Code with Circular RNA” to share how circular RNA is unlocking a new frontier in brain health. In this episode, we explore: • The breakthrough science behind circular RNA • Circular Genomics’ expanding product pipeline • The launch of our Alzheimer’s research-use-only (RUO) assay • A systems-level approach to Alzheimer’s that goes beyond the traditional amyloid-tau model • What’s next for commercialization Tune in to hear how circular RNA is reshaping diagnostics: Watch Tower Research: https://lnkd.in/grTbiqBU Spotify: https://lnkd.in/g6Ew9F4Q Apple Podcasts: https://lnkd.in/gDatTxkB

Did you know that 75% of dementia cases worldwide go undiagnosed? 🌍 For too long, getting an answer has meant jumping through hoops. Traditional diagnostics rely on a complex ""triple threat"" of testing: Cognitive Testing: Stressful exams that often catch the disease too late. Lumbar Punctures: Invasive and intimidating procedures. High-Tech Imaging: Expensive PET or MRI scans with limited availability. While these tools are effective, they aren't scalable—resulting in millions of people being left in the dark during the most critical window for treatment. At Circular Genomics, our research and technology using Circular RNA (circRNA) aims to provide insight into the underlying biology of Alzheimer's Disease, offering a clearer path toward early detection and personalized care. Learn more: https://lnkd.in/gmgEPGwM"

In her moving story, Vanessa Louise Carter shares the reality of being a “sandwich generation” caregiver—raising a young son while supporting parents living with Alzheimer’s and FTD. Her journey highlights the immense challenges caregivers face: balancing a career, family, and ensuring a loved one’s safety, cognitive stimulation, and moments of joy. It also underscores the critical importance of early detection—because timely diagnosis is not just a medical milestone, it’s a chance to plan for the future. Read Vanessa’s full story: https://lnkd.in/gqGyEhZy

Alzheimer’s is the 6th leading cause of death in the U.S., and someone develops it every ~65 seconds. Early detection is critical. Identifying cognitive changes sooner gives patients the opportunity to take proactive steps to manage risk and plan for the future. At Circular Genomics, we’re developing non-invasive blood-based tests to detect Alzheimer’s earlier, helping empower patients and clinicians with actionable insights when it matters most. Learn more: https://lnkd.in/g4Xsxr68 #AlzheimersAwareness #EarlyDetection #BrainHealth #CognitiveWellness #CircularGenomics #BloodBiomarker

Studies show that lifestyle changes—regular exercise, a balanced diet, mental stimulation, and routine health check-ups—can improve cognition in older adults at risk of cognitive decline. The U.S. POINTER trial, the first large-scale RCT in the U.S., demonstrates that accessible, multidomain lifestyle interventions can protect cognitive function across diverse populations. 🔑 Why it matters: Early detection helps identify who is at risk, giving patients and caregivers the chance to take proactive steps to slow or delay cognitive decline. Everyday lifestyle choices can truly make a difference. Learn more about the study: https://lnkd.in/gbtPQMnd #BrainHealth #EarlyDetection #CognitiveWellness #AlzheimersPrevention #HealthyAging #USPOINTER

On #EmployeeAppreciationDay, we recognize the remarkable team behind Circular Genomics. Your dedication to advancing care for patients with psychiatric and neurological disorders is what drives our mission forward. Thank you for your passion, innovation, and relentless commitment to making a difference for patients and their families. #CircularGenomics #Teamwork #Innovation

Circular Genomics will be at AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases in Copenhagen 🇩🇰 📆 March 17–21, 2026 Meet our team members Jessica DeHart and Olivia Tucker and learn how circular RNA is shaping the future of blood-based biomarkers for neurodegenerative disease. 👉 Book a meeting with us at the conference: https://lnkd.in/gQSF89CN

Circular RNAs (circRNAs) are emerging as a powerful new class of biomarkers—closely tied to the biological pathways that drive Alzheimer’s disease progression, not just its symptoms. This opens the door to earlier, more precise diagnosis, helping patients, families, and clinicians gain critical time to plan, intervene, and care with greater confidence. At Circular Genomics, we’re advancing circRNA innovation to reshape how Alzheimer’s is detected and managed—because earlier insight can mean better outcomes and renewed hope. 🔗 Read our whitepaper to learn more: https://lnkd.in/gjJYhATc #AlzheimersResearch #Biomarkers #BrainHealth #PrecisionMedicine